Further investigations towards novel glycopeptide/b-lactam heterodimers are reported. Employing a multivalent approach to drug discovery, vancomycin and cephalosporin synthons, 4, 2, 5 and 10, 18, 25 respectively, were chemically linked to yield heterodimer antibiotics. These novel compounds were designed to inhibit Grampositive bacterial cell wall biosynthesis by simultaneously targeting the principal cellular targets of both glycopeptides and b -lactams. The positional attachment of both the vancomycin and the cephalosporin central cores has been explored and the SAR is reported. This novel class of bifunctional antibiotics 28ϳ36 all displayed remarkable potency against a wide range of Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). A subset of compounds, 29, 31 and 35 demonstrated excellent bactericidal activity against MRSA (ATCC 33591) and 31 and 35 also exhibited superb in vivo efficacy in a mouse model of MRSA infection. As a result of this work compound 35 was selected as a clinical candidate, TD-1792.
Introduction
The medical community is increasingly concerned by the incidence of multi-drug resistant bacterial infection. The emergence of deadly and virulent Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and penicillin-resistant Streptococus pneumoniae (PRSP) have prompted an intensified search for novel therapies [1] . Applying a multivalent approach to drug discovery we recently reported the first examples of glycopeptide/blactam heterodimers which exhibited remarkable potency against Gram-positive pathogens [2] . Due to the physical proximity of the principal cellular targets of glycopeptides (lipid intermediate II) and b -lactams (transpeptidase domain of penicillin binding protein, PBP), and their sequential role in the cell-wall biosynthetic pathway, we reasoned that a single molecule that inhibited both targets in a bifunctional manner may provide enhanced potency and bactericidal activity. Multivalency is a phenomenon whereby multiple, simultaneous, energetically coupled ligand: receptor interactions enhance the overall affinity and selectivity of binding [3] . Multivalency is common in natural systems; for example, in controlling cell-cell interactions and in the adhesion of a virus particle to an erythrocyte [4] . Recent literature suggests that multivalency may also find applicability in the design of small molecule ligands [5] . Homodimers and oligomers of vancomycin [6] , paclitaxel [7] and opioids [8] have all been reported to enhance binding relative to their constitutive monomeric components [9] . In addition to enhanced efficacy it has been proposed that multivalent molecules may also offer physicochemical advantages and allow coupling of pharmacophores with distinct mechanisms of action [10] .
We previously reported the discovery of compound 1 which was designed to link a vancomycin synthon (attachment point through the vancosamine amino group) with a specific cephalosporin, b-lactam motif (attachment through the C3 pyridinium substituent) using a simple diamide linear alkyl linkage. This compound exhibited excellent potency against a range of Gram-positive pathogens (Table 1 ) and displayed rapid bactericidal activity against S. aureus ATCC 33591 (MRSA), achieving a 3-log CFU/ml reduction after only 4 hours at a concentration of 0.5 mg/ml.
In this paper, we describe further efforts to explore and optimize our multivalent approach to antibacterial drug discovery and report structure activity relationships with regard to the attachment points to both the glycopeptide and b-lactam components.
Multivalent Design
Consideration of the central vancomycin (V) core 2 used to construct heterodimer 1 revealed a number of potential attachment points, Fig. 1 . In addition to modification of the vancosamine amino group (V V ) [2] , vancomycin 2 can be selectively derivatized through the carboxyl terminus (V C ) or the 4Ј, resorcinol-like (V R ) position on the aromatic side chain of amino acid 7. Employing an ethyl primary amino motif attached to the vancosamine amino group as previously described [2] , allows linkage via an amide bond to vancomycin whilst preserving the basicity at the V V position. This has been shown to be important for the antibacterial activity of vancomycin and chloroeremomycin derivatives [11] . Amide bond formation at the C-terminus of vancomycin V C is typically well tolerated [12] and Mannich aminomethylation and susbsequent amide bond formation at the V R -position additionally provides compounds with in vitro activity comparable to the parent vancomycin [11, 13] . The cephalosporin (C) core 3 was previously derivatized at the C3 pyridinium susbtituent (C PY ) by a methyl amino moiety, Fig. 1 [2] . Introduction of a similar amino moiety at both the oxime (C OX ) and aminothiazole (C AM ) of the chloro-substituted aminothiazolyl(syn-methoxyimino)acetyl moiety at the C7 position of the cephalosporin, provides two additional attachment points.
The combination of vancomycin attachment points (V V , V C , V R ) with cephalosporin attachment points (C PY , C OX , C AM ) was explored by the preparation of amide-linked glycopeptide/b -lactam heterodimers 28ϳ36. A representation of the nine possible heterodimer combinations is presented using three specific vancomycin analogues, 4, 2, 5 (V V , V C , V R respectively; Scheme 1) and three specific cephalosporin derivatives, 10, 18, 25 (C PY , C OX , C AM respectively; Schemes 2ϳ4). The V V and V R linked heterodimers (28, 29, 30 and 31, 32, 33 respectively) use adipic acid as the connecting di-acid whilst the V C linked heterodimers (34, 35, 36) are connected by direct amide bond formation at the C-terminus of vancomycin 2.
Chemistry
The synthon 4 for V V attachment of vancomycin was prepared as previously described [2] . The V C synthon 2 merely required vancomycin itself. The V R synthon 5 was prepared by Mannich aminomethylation of vancomycin 2 with ethylenediamine and formaldehyde (Scheme 1) [13, 14] . By limiting the amount of formaldehyde used we were able to suppress side reactions [15] as well as overalkylation.
The C PY derivatized cephalosporin monomer core 10 (RϭH) was prepared from 7-amino-3-chloromethyl-3-cephem-4-carboxylic acid p-methoxybenzyl ester hydrochloride salt (ACLE) in a route similar to that previously reported for the methyl aminoethyl substituted, pyridinium compound (RϭEt) used to prepare 1 (Scheme 2) [2] . The ethyl substituent was shown to have minimal effect on potency. Chlorination of aminothiazolyl(synmethoxyimino)acetic acid 6 was effected with Nchlorosuccinimide (NCS) in DMF and the resulting acid 7 was coupled to ACLE using N- [3-dimethylaminopropyl] -NЈ-ethylcarbodiimide hydrochloride (EDCI) in the presence of collidine. The chloro leaving group at C-3 of compound 8 was displaced with N-Boc-4-(aminomethyl)-pyridine. Boc and para-methoxybenzyl (PMB) protecting group deprotection of the pyridinium cephalosporin 9 was effected in situ with TFA in CH 2 Cl 2 to afford the desired blactam C PY core 10.
Introduction of a propyl amino group to the oxime of the aminothiazole of 3 resulted in the C OX synthon 18 (Scheme 3). Bromopropylamine 11 was first protected as its N-Boc derivative 12 which was subsequently used to alkylate trityl-protected ethyl aminothiazolyl(synhydroxyimino)acetate 13 in the presence of cesium carbonate and tetrabutylammonium iodide. The resultant ester 14 was hydrolyzed to the acid and chlorinated with NCS in chloroform. The acid 15 was converted to the acid chloride with phosphorous oxychloride and coupled in situ with ACLE to afford the cephalosporin 16. Pyridine and sodium iodide in acetone effected displacement of the C-3 chloro leaving group of 16 and subsequent global deprotection of the resulting pyridinium compound 17 with TFA in CH 2 Cl 2 yielded the C OX synthon 18.
The C AM synthon 25 incorporated a b -alanine motif at the amine of the aminothiazole (Scheme 4). N-Boc-balanine was coupled to ethyl aminothiazolyl(synmethoxyimino)acetate 19 with EDCI and the subsequent ester 20 hydrolyzed to the acid 21. Following a similar process to that described above, the acid 21 was chlorinated in DMF and coupled with ACLE using EDCI to give 23. The C-3 chloro group was displaced with pyridine and deprotection of the Boc and PMB protecting groups with TFA afforded the C AM synthon 25.
The V and C synthons 4, 5 and 10, 18, 25 respectively, were covalently linked through the formation of an amide bond at each terminus of a linking adipic acid moiety. The di-1-hydroxyazabenzotriazole(HOAt)-ester 27 of adipic acid 26 was prepared and treated sequentially with the relevant V and C synthon, in the presence of collidine (Scheme 5; representative example 33). The products were purified by reverse phase-HPLC to afford the glycopeptide/b -lactam heterodimers 28ϳ33. The V C synthon 2 was directly coupled with the individual C synthons 10, 18, 25 using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and HOAt in DMSO and DMF to afford heterodimers 34ϳ36 (Scheme 6; representative example 35). 
Results and Discussion
The glycopeptide/b -lactam heterodimers were screened against a panel of bacterial strains, representing both the major Gram-positive human pathogens (staphylococci, enterococci and streptococci) and important drug resistance phenotypes. MICs for compound 1, heterodimers 28ϳ36, C synthons 10, 18, 25 and V synthons 4, 5, 2 are presented in Table 1 .
Intriguingly, it was observed that all the combinations of the V (4, 5, 2) and C synthons (10, 18, 25) resulted in heterodimers (28ϳ36) with excellent potency against a range of the Gram-positive organisms tested (notably MSSA and MRSA with MIC values typically 0.05 mg/ml). The individual monomeric V synthons (4, 5, 2) and C synthons (10, 18, 25) were all considerably less potent (Ͼ30 fold) than the heterodimers (28ϳ36) against all the Staphylococcus pathogens tested. However, against EFSVA the heterodimers (28ϳ36) (0.78ϳ25 m g/ml) were comparable in potency to the C synthons (10, 18, 25) (3.13ϳ25 m g/ml) and against EFMVA all the compounds tested were essentially inactive (Ͼ50 mg/ml). With regard to specific heterodimer SAR, linkage via V V , V R or V C appears to have little effect on the potency profile. For example, attaching the C OX lactam 18 to the three V synthons (4, 5, 2) results in 29, 32 and 35, respectively, which share almost identical MIC profiles. This trend is similarly observed for the series of C PY and C AM linked heterodimers (28, 31, 34 and 30, 33, 36 respectively). Consideration of the C attachment points reveals that the C AM compounds linked to V V and V R (30 and 33, respectively) show reduced potency against PRSP (0.2 mg/ml) compared to the C PY and C OX linked analogues (28, 31 and 29, 32 respectively) (all 0.05 m g/ml). In addition, activity against the EFSVA strain demonstrates a general trend that the C OX linked compounds (29, 32, 35; 0.78 mg/ml) are superior to the C PY linked compounds (28, 31, 34; 1.56ϳ3.13 mg/ml) which are in turn superior to the C AM linked compounds (30, 33, 36; Ͼ25 mg/ml). The minor SAR observed between all of the heterodimer compounds (28ϳ36) indicate that the relative spatial orientation (determined either by positional attachment V V , V C , V R , C PY , C OX , C AM , or linker length; V C compounds have a shorter linker length than both V V and V R ) of both the glycopeptide and the b-lactam component is not critical to determining the enhanced potency of the heterodimers relative to the monomeric components. This observation makes it difficult to envision simultaneous binding at both cellular targets of the heterodimers. An alternative proposal is that the heterodimers localize two active components which results in synergistic inhibition of cell wall synthesis [2] .
The bactericidal activity of a set of compounds against S. aureus ATCC 33591 (MRSA) was determined and all were shown to be superior to vancomycin 2, which was static at doses of 0.25 and 1.0 mg/ml. For the C OX linked set (29, 32, 35) it appears that the V V and V C attachment points demonstrate superior cidality with both 29 and 35 achieving a 3-log CFU/ml reduction after only 4 hours at 0.25 m g/ml or 1 hour at 1.0 m g/ml, respectively. The V R attached compound 32 is static at 0.25 mg/ml and takes 4 hours to achieve cidality at 1.0 m g/ml. Within the V R attached set the C PY linked compound 31 shows similar cidality to the C OX heterodimer 32, both being superior to the C AM derivative 33 (cidal at 1.0 mg/ml after 24 hours).
The excellent in vitro activity profiles described for the heterodimers 31 and 35 were tested in vivo using the murine neutropenic thigh model of MRSA. Upon IV administration, 31 and 35 exhibited ED 50 values of 0.11 and 0.19 mg/kg, respectively. These are both 40 fold more efficacious than vancomycin 2 which displays an ED 50 value of 8.1 mg/kg in this assay.
In summary, we have extended our initial multivalent approach towards glycopeptide/b -lactam heterodimers to explore the various attachment points with which to connect vancomycin and cephalosporin cores. To our surprise, all combinations of heterodimers 28ϳ36 exhibited superb potency against a range of important Gram-positive bacteria. In keeping with previous observations, a subset of these potent compounds also demonstrated rapid bactericidal activity against MRSA [2] . Various SAR trends have been highlighted and two of the most attractive compounds 31 and 35 have been shown to exhibit in vivo efficacy Ͼ40 fold that of vancomycin against an important MRSA pathogen. As a result of this work compound 35 was selected as a clinical candidate, TD-1792. Additional SAR, further properties of these compounds and data to support the multivalent mechanism of action will be reported in future articles.
Experimental

General Methods
Reagents and solvents were used as received from commercial suppliers and all reactions were carried out at room temperature and without rigorous exclusion of ambient atmosphere unless otherwise noted. Ion-spray mass spectra (IS-MS) were obtained on a PE Sciex API 150EX mass spectrometer operating in positive ion mode. NMR spectra were recorded at 300 MHz. Chemical shifts 
HPLC Methods
Analytical: Reactions were monitored by analytical reversed-phase HPLC (RP-HPLC) with an HP1100 instrument using a 2.1 mmϫ50 mm, 3.5 m m C14 Zorbax Plus Bonus-RP column with UV detection at 214 nm. For the analytical separations, a 0.5 minutes isocratic period was followed by a 4.5 minutes gradient of 2ϳ90% CH 3 CN in H 2 O with 0.1% TFA.
Preparative: Compounds were purified by preparative RP-HPLC on a Varian ProStar system using 2.5 or 5.0 cmϫ25 cm Rainin Dynamax columns and flow rates of 15 or 50 ml/minute, respectively. Separations were accomplished with a gradient of 5ϳ60% CH 3 CN in H 2 O containing 0.1% TFA over 90 minutes.
V R Synthon 5
Ethylenediamine (7.0 ml, 100 mmol) and 1.0 N NaOH (50 ml) were added to a stirred solution of vancomycin hydrochloride (20 g, 13 mmol) in H 2 O (100 ml) at 0°C. 
C PY Synthon 10
N-Chlorosuccinimide (35 g, 0.26 mol) was added to a stirred solution of 2-amino-a -(methoxyimino)-4-thiazoleacetic acid 6 (50 g, 0.25 mol) in DMF (500 ml) at room temperature and the reaction mixture stirred overnight. The light brown solution of resultant 7 was used without further purification. ACLE (101.5, 0.25 mol), 2,4,6-collidine (33.5 ml, 0.25 mmol) and EDCI (53 g, 0.275 mol) were added and the reaction mixture stirred for 2 hours at room temperature. The reaction mixture was precipitated into H 2 O (3 liters) and the solids filtered, washed with H 2 O (2ϫ1 liter), saturated aqueous sodium bicarbonate (500 ml), H 2 O (4ϫ500 ml) and dried. The dry solid was taken up in CH 2 Cl 2 (500 ml), slowly stirred and the precipitate which formed filtered and washed with additional CH 2 Cl 2 until the washings were colorless. The precipitate was collected and dried to afford 8 (74 g, 51%). Me 2 CO (250 ml) was added to a mixture of 8 (50 g, 85 mmol) and sodium iodide (13 g, 85 mmol) in the dark, under an atmosphere of nitrogen at room temperature. The reaction mixture was stirred for 30 minutes and then a solution of 4-(N-tert-butoxycarbonyl)aminomethyl pyridine (27 g, 130 mmol) in Me 2 CO (30 ml) was added. The reaction mixture was stirred for 2 hours and then 0.1 N HCl (1.4 liters) was added to produce a gummy precipitate. The solvent was decanted and the gummy residue treated with H 2 O (800 ml) to give a solid. The H 2 O was decanted and the solid dissolved in a mixture of EtOAc/EtOH (4 : 1, 1 liter) and washed with brine (500 ml), dried (MgSO 4 ), filtered and concentrated in vacuo to afford 9 (70 g, 78% purity by HPLC Anisole (35 ml) was added to a stirred solution of crude 9 (70 g) in CH 2 Cl 2 (550 ml). TFA (150 ml) was added to the reaction mixture at room temperature which was stirred for 2 hours and then concentrated in vacuo. The residue was diluted with diethyl ether (1 liter) and the precipitate filtered, washed with diethyl ether, stirred in H 2 O (200 ml), filtered and dried. The residue was purified by RP-HPLC to afford 10·2TFA salt (30 g, 46% from 8). 
C OX Synthon 18
A solution of tert-butoxycarbonyl anhydride (112.6 g, 516 mmol) in THF (200 ml) was added to a stirred solution of 3-bromopropylamine hydrobromide 11 (100 g, 457 mmol) and triethylamine (190 ml) in THF (1.6 liters) at 0°C. The reaction mixture was warmed to room temperature, stirred overnight and then filtered. The filtrate was concentrated in vacuo and the residue diluted with hexane (1.5 liters) and stored at Ϫ20°C for 3 days. The solvent was decanted from the formed solid which was dried to afford 12 (101 g, 93%) as a white crystalline solid. Cesium carbonate (230.8 g, 709 mmol) and tetrabutylammonium iodide (18.7 g, 51 mmol) were added to a stirred solution of 13 (100 g, 219 mmol) in DMF (700 ml) at room temperature. A solution of 12 (50.6 g, 213 mmol) in DMF (100 ml) was added dropwise to the reaction mixture over 30 minutes. After 2 hours, the reaction mixture was filtered and the solids washed with DMF (200 ml). The filtrate was diluted with EtOAc (2 liters) and washed with 1.0 N HCl (700 ml), saturated aqueous sodium bicarbonate (700 ml) and brine (500 ml). The organic layer was dried (Na 2 SO 4 ), filtered and concentrated in vacuo to give a residue which was dissolved in boiling EtOH (250 ml). Upon cooling a solid formed which was filtered, washed with cooled EtOH (50 ml) and dried to afford 14 (117 g, 90%) as an off-white powder. 1 3 . ACLE (37.5 g, 93 mmol) was added to a stirred solution of 15 (66.2 g, 107 mmol) in THF (850 ml) and the reaction mixture cooled to Ϫ45°C. 2,4,6-Collidine (30.6 ml, 232 mmol) was added to the reaction mixture followed by phosphorous oxychloride (12.1 ml, 130 mmol). The reaction mixture was stirred at Ϫ45°C for 10 minutes and then carefully quenched with H 2 O (650 ml) and diluted with EtOAc (650 ml). The layers were separated and the aqueous layer further extracted with EtOAc (650 ml). The combined organic layers were washed with H 2 O (650 ml) and brine (650 ml), dried (MgSO 4 ), filtered and concentrated in vacuo to afford 16 (101.2 g, Ͼ100%) as a brown-red solid. Sodium iodide (7.7 g, 51.4 mmol) was added to a stirred solution of 16 (49.9 g, 51.4 mmol) in Me 2 CO (220 ml) in the dark, under an atmosphere of nitrogen at room temperature. The reaction mixture was stirred for 80 minutes and then pyridine (5.82 ml, 71.9 mmol) was added. The reaction mixture was stirred for 150 minutes and then added to diethyl ether (1 liter). The resultant precipitate was filtered, washed with diethyl ether (3ϫ100 ml) and dried in vacuo. The solid was further washed with diethyl ether (3ϫ100 ml) and dried to afford 17 (46.7 g, 90%) as a tan solid. 1 C AM Synthon 25 EDCI (61.4 g, 0.320 mol) and DMAP (33.1 g, 0.271 mol) were added to a stirred solution of aminothiazole 19 (56.5 g, 0.246 mol) and Boc-b -alanine (55.9 g, 0.296 mol) in DMF/CH 2 Cl 2 (4 : 1, 700 ml) at room temperature, under an atmosphere of nitrogen. After 18 hours the reaction mixture was diluted with EtOAc (1.7 liters) and washed with 1.0 M HCl (2ϫ500 ml), saturated aqueous sodium bicarbonate (500 ml) and brine (500 ml). The organic layer was dried (MgSO 4 ), filtered and concentrated in vacuo to afford 20 (99 g, 100%) as a foam which was used without further purification. with EtOAc (500 and 250 ml). The aqueous layer was concentrated in vacuo and the crude residue partitioned between CHCl 3 (800 ml) and 1.0 M phosphoric acid (600 ml). The acidic aqueous layer was further extracted with CHCl 3 (800 ml) and the organic extracts combined, dried (MgSO 4 N-Chlorosuccinimide (6.9 g, 52 mmol) was added to a stirred solution of 21 (19.3 g, 52 mmol) in DMF (100 ml) at room temperature, under an atmosphere of nitrogen. The reaction mixture was stirred for 18 hours and the light brown solution of resultant 22 was used without purification. The reaction mixture was diluted with DMF (40 ml) and EDCI (14.9, 78 mmol), HOAt (10.6 g, 78 mmol) and 2,4,6-collidine (20.6 ml, 156 mmol) added. The reaction mixture was stirred at room temperature for 20 minutes and then cooled to 0°C and a solution of ACLE (22.1 g, 54 mmol) and 2,4,6-collidine (10.3 ml, 78 mmol) in DMF (170 ml) added. The reaction mixture was warmed to room temperature over 4 hours, and then diluted with EtOAc (1.2 liters) and washed with 1.0 M HCl (2ϫ400 ml) and saturated aqueous sodium bicarbonate (2ϫ400 ml). The organic layer was dried (MgSO 4 ), filtered and concentrated in vacuo to afford 23 (14.94 g, 38%) as an off-white solid which could be used crude, without further purification. A sample was purified by flash chromatography (EtOAc/hexane, 1 : 1 to 5 : 4 to 3 : 2 to 2 : 1 
Di-HOAt Ester of Adipic Acid 27
A solution of adipic acid (6.63 g, 45.4 mmol), HOAt (15.28 g, 99.8 mmol) and EDCI (19.13 g, 99.8 mmol) in DMF (80 ml) was stirred at room temperature, under an atmosphere of nitrogen, overnight. The reaction mixture was diluted with CH 2 Cl 2 (500 ml) and washed with saturated aqueous sodium bicarbonate (2ϫ200 ml) and brine (2ϫ200 ml). The organic phase was dried (MgSO 4 ), filtered and concentrated in vacuo to afford 27 as a white solid was used without further purification.
Representative Example: Glycopeptide-b b-lactam Heterodimers 31 10·2TFA salt (1.0 g, 1.3 mmol) was added to a stirred solution of crude di-HOAt adipic ester 27 (2.48 g, 6.5 mmol) in DMF (50 ml) at room temperature. The reaction mixture was cooled to 0°C and 2,4,6-collidine (0.34 ml, 2.6 mmol) added and stirring continued for 15 minutes. TFA (0.3 ml, 3.9 mmol) was added to quench the reaction which was added to EtOAc (400 ml) and the resultant precipitate centrifuged washed with EtOAc, the EtOAc decanted and the solid dried. A solution of 5 (3.86 g, 1.95 mmol) in DMF (40 ml) was added to the solid and the reaction mixture stirred and cooled to 0°C. 2,4,6-Collidine (1.03 ml, 7.8 mmol) was added and the reaction mixture stirred for 20 minutes and then quenched with TFA (0.80 ml, 10.4 mmol) and added to CH 3 CN (400 ml). The resultant precipitate was filtered and purified by RP-HPLC to afford 31·3TFA salt (740 mg, 23%) as a white powder. IS-MS, calcd. m/z for [M ϩ ]: 2170.5; obsd. 2171.8.
Representative Example: Glycopeptide-b b-lactam Heterodimers 35
A solution of PyBOP (1.3 g, 2.6 mmol) and HOAt (0.35 g, 2.6 mmol) in DMF (40 ml) was added to a stirred solution of vancomycin hydrochloride 2 (4.2 g, 2.8 mmol) in DMSO (40 ml) at room temperature. DIPEA (0.98 ml, 5.7 mmol) was subsequently added and the reaction mixture stirred for 30 minutes and then quenched with TFA (0.44 ml, 5.7 mmol). The reaction mixture was cooled to 0°C and a solution of 18·2TFA salt (2.6 mmol) in DMF (20 ml) added followed by 2,4,6-collidine (1.5 ml, 11.4 mmol). The reaction mixture was stirred for 4 hours and then quenched with TFA (1.1 ml) and added to diethyl ether. The resultant precipitate was centrifuged, washed with diethyl ether, the ether decanted and the solid dried and then purified by RP-HPLC. The anion of the salt was exchanged using Amberlyte resin to afford 35·3HCl salt (1.4 g, 26%) Determination of in Vitro Antimicrobial Activity MIC susceptibility determinations were performed using a standard broth microdilution assay according to the recommendation of the National Committee for Clinical Laboratory Standards [16] .
Determination of Bactericidal Activity
Time-kill assays were performed in broth media. Log-phase cultures of bacteria with a final density of approximately 10
6 CFU/ml were tested. Immediately after inoculation, the first samples (100 ml) were taken and constituted the time point 0 hour. Test tubes were incubated in ambient air at 35°C with constant agitation for 24 hours and were sampled at various time points. Samples were diluted in saline and colony counts were performed by applying 100 ml of samples directly on solid media. Colonies were counted after 24 hours incubation.
Determination of in Vivo Efficacy in Neutropenic Mouse
Thigh Assay Female mice were rendered neutropenic with cyclophosphamide and infected in the thigh with the organism. Infected animals were dosed intravenously beginning at 1 hour post-infection with vehicle or the appropriate dose of 31/35. At 24 hours post-infection, animals were euthanized and thighs were harvested, homogenized and processed to determine bacterial titer [17] .
